Use of interleukin-2 in immunotherapy of human immunodeficiency virus infection

BioDrugs

Volumn 10, Issue 3, 1998, Pages 215-225

  Reier, Alice ^a   Mitsuyasu, Ronald T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031680190     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810030-00005     Document Type: Review

References (54)

1. Marincola FM. Interleukin-2. Biol Ther Updates 1994; 4: 1-16
2. Seder RA, Grabstein KH, Berzofsky JA, et al. Cytokine interactions in human deficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med 1995 Oct; 182(4): 1067-77
3. Adachi Y, Oyaizu N, Than S, et al. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: correlation with its ability to block culture-induced down modulation of Bcl-2. J Immunol 1996 Nov; 157 (9): 4184-93
4. Kaplan G, Cohn ZA, Smith KA. Rational immunotherapy with interleukin-2. Biotechnology 1992 Feb; 10: 157-62
5. Kinter A, Fauci AS. Interleukin-2 and human deficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Immunol Res 1996; 15 (1): 1-5
6. Butera, ST. Cytokine involvement in viral permissiveness and the progression of HIV disease. J Cell Biochem 1993; 53: 336-42
7. Jacobson EI, Pilaro F, Smith KA. Rational interleukin-2 therapy for HIV-positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996 Sep; 93 (19): 10405-10
8. Weissman D, Daucher J, Barker T, et al. Cytokine regulation of HIV replication induced by dendritic cell-CD4-positive T cell interactions. AIDS Res Hum Retroviruses 1996; 12 (9): 759-67
9. Levine BL, Mosca JD, Riley JL, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996 Nov; 272: 1939-43
10. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-76
11. Flores I, Casaseca T, Martinez AC, et al. Phosphatidic acid degeneration through interleukin-2 (IL-2)-induced alpha diacylglycerol kinase activation is an essential step in IL-2 lymphocyte proliferation. J Biol Chem 1996 Apr; 271 (17): 10334-40
12. Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular toxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991 Dec; 50 (6): 628-40
13. Puri PK, Leland P, Aggarwal BB. Constitutive expression of human deficiency virus type 1 tat gene inhibits interleukin-2 and interleukin-2 receptor expression in a human CD4+ T lymphoid (H9) cell line. AIDS Res Hum Retroviruses 1995 Jan; 11 (1): 31-40
14. Honda M, Kitamura K, Matsuda K, et al. Soluble IL-2 receptor in AIDS. J Immunol 1989 Jun; 142 (12): 4248-55
15. Tsunetsugu-Yokota Y, Honda M. Effect of cytokines on HIV release and IL-2 receptor alpha expression in monocytic cell lines. J Acquir Immun Defic Syndr Hum Retrovirol 1990 Aug; 3 (5): 511-6
16. Secreti I, Spear GT. Complement activation by HIV-1 infected target cells enhances IL-2 stimulated but not unstimulated ADCC activity mediated by peripheral blood mononuclear cells. Clin Immunol Immunopathol 1996 Jan; 78 (1): 78-82
17. Lin SJ, Roberts RL, Ank BJ, et al. Human immunodeficiency virus (HIV) type-1 gp120-specific cell-mediated toxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects: enhancement with interleukin-2 (IL-2), IL-12, and IL-15. Clin Immunol Immunopathol 1997 Feb; 82 (2): 163-73
18. Westendorp MO, Li-Weber M, Frank RW, et al. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 1994 Jul; 68 (7): 4177-85
19. Lederman MM. Host-directed and immune-based therapies for human immunodeficiency virus infection. Ann Intern Med 1995; 122: 218-22
20. Winkelstein A, Kingsley LA, Weaver LD, et al. Defective T cell colony formation and IL-2 receptor expression in HIV-infected homosexuals: relationship between functional abnormalities and CD4 cell numbers. J Acquir Immune Defic Syndr 1989; 2 (4): 353-8
21. Winkelstein A, Kingsley LA, Klein RS, et al. Detective T-cell colony formation and IL-2 receptor expression at all stages of HIV infection. Clin Exp Immunol 1988 Mar; 71 (3): 417-22
22. Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus sero-positive individuals. J Clin Invest 1993 Mar; 91 (3): 759-65
23. Clerici M, Balotta C, Meroni L, et al. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res Hum Retroviruses 1996 Jul; 12 (11): 1053-61
24. Bost KL, Hahn BH, Saag MS, et al. Individuals infected with HIV possess antibodies against IL-2. Immunology 1988 Dec; 65 (4): 611-5
25. Scott-Alzara D, Vuillier M, Marasescu M, et al. Serum levels of IL-2, IL-1α, TNF-α and soluble receptor of IL-2 in HIV-1-infected patients. AIDS Res Hum Retroviruses 1991 Apr; 7 (4): 381-6
26. Poli G, Fauci A. The effect of cytokines and pharmacologic agents on chronic HIV-intection. AIDS Res Hum Retroviruses 1992 Feb; 8(2): 191-7
27. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-7
28. Rubin LA, Jay G, Nelson D. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986; 137: 3841-4
29. Cohen JJ. Apoptosis. Immunol Today 1993; 14 (3): 126-30
30. Radrizzani M, Accorneo P, Amidei A, et al. IL-12 inhibits apoptosis induced in a human Th1 clone by gp120/CD4 cross-linking and CD4/TCR activation or by IL-2 deprivation. Cell Immunol 1995 Mar; 161 (1): 14-21
31. Meyaard L, Otto SA, Jonker RR, et al. Programmed cell death. Science 1992; 257: 217-9
32. Salmon M, Pilling D, Borthwick NJ, et al. The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur J Immunol 1994; 24: 892-9
33. Miyawawaki T, Uehara R, Nibu T, et al. Differential expression of apoptosis-related Fas antigen on lymphocytes subpopulation in human peripheral blood. J Immunol 1992; 149: 3753
34. Pandolfi F, Pierdominici M, Oliva A, et al. Apoptosis-related mortality in vitro of mononuclear cells from patients with HIV infection correlates with disease severity and progression. J Acquir Immun Defic Syndr Hum Retrovirol 1995 Aug; 9 (5): 450-8
35. Clerici M, Sarin A, Berzofsky JA, et al. Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and affected by lymphotoxin. AIDS 1996; 10 (6): 603-11
36. Clerici M, Balotta C, Salvaggio A, et al. Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood 1996 Jul; 88 (2): 574-9
37. Mor F, Cohen IR. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. J Immunol 1996; 156: 515-22
38. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332: 567-75
39. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996 Oct; 335 (18): 1350-6
40. Kinter AL, Bende SM, Hardy EC, et al. Interleukin-2 induces CD8+ cell-mediated suppression of human immunodeficiency virus replication in CD4+ cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci 1995 Nov; 92 (24): 10985-9
41. Teppler H, Kaplan G, Smith K, et al. Efficacy of the low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with immunodeficiency virus type-1 infection. J Infect Dis 1993 Feb; 167 (2): 291-8
42. Wood R, Montoya JG, Kundu SK, et al. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human deficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993 Mar; 167 (3): 519-25
43. H2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc Natl Acad Sci USA 1995 Nov; 92: 11135-9
44. Vyarkarman A, Matear PM, Martin SJ, et al. Th1 cells specific for HIV-1 gag p24 are less efficient than Th0 cells in supporting HIV replication, and inhibit virus replication in Th0 cells. Immunology 1995 Sep; 86 (1): 85-96
45. Chehimi J, Ma X, Chouaib S, et al. Differential production of interleukin-10 during human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1996; 12 (12): 1141
46. Hagiwara E, Sacks T, Leitman-Klinman SF, et al. Effect of HIV infection on the frequency of cytokine-secreting cells in human peripheral blood. AIDS Res Hum Retroviruses 1996 Jan; 12 (2): 127-33
47. Naif HM, Chang J, Ho-Shon M, et al. Inhibition of human immunodeficiency virus in differentiating monocytes by interleukin-10 occurs in parallel with inhibition of cellular RNA expression. AIDS Res Hum Retroviruses 1996; 12(13): 1237-45
48. Koostra NA, Wout AB, Huisman HG, et al. Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages. J Virol 1994 Nov; 68 (11): 6967-75
49. Saville MW, Taga K, Foli A, et al. Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte-macrophage lineage. Blood 1994 Jun; 83 (12): 3591-9
50. Fan J, Bass HZ, Fahey JL. Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection. J Immunol 1993 Nov; 151 (9): 5031-40
51. Sneller MC. Consensus symposium on combined antiretroviral therapy; overview of interferon and IL-2 combinations for the treatment of HIV infection. Antiviral Res 1996 Jan; 29 (1): 105-9
52. Kinter AL, Poli G, Fox L, et al. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995 Mar; 154 (5): 2248-59
53. Bernstein ZP, Porter MM, Gould M, et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995 Nov; 86 (9): 3287-94
54. Davey RT, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type-1-infected persons. J Infect Dis 1997; 175: 781-9